ACACA and metabolic dysfunction-associated steatohepatitis: Interestingly, in patients with NASH and fibrosis, fenofibrate administered 2 weeks before the addition of the ACC inhibitor, firsocostat, not only mitigated hypertriglyceridemia, but also improved liver biochemistry compared to icosapent ethyl (Vascepa) (362).